Tests thymosin β4 for diabetic peripheral neuropathy (DPN) in type II db/db mice and investigates miR-146a as the mechanistic mediator. TB4 treatment for 8 weeks significantly improved motor and sensory nerve conduction velocities, increased intraepidermal nerve fiber density, and enhanced endoneurial vascularization. TB4 upregulated miR-146a, suppressing TLR/IRAK1/NF-κB neuroinflammatory signaling. Establishes a TB4→miR-146a→NF-κB suppression axis for neurovascular remodeling in diabetic neuropathy—addressing an underserved complication affecting >50% of long-standing diabetic patients.
Wang, Lei; Chopp, Michael; Lu, XueRong; Szalad, Alexandra; Jia, LongFei; Liu, Xian Shuang; Wu, Kuan-Han; Lu, Mei; Zhang, Zheng Gang